
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Oncol.
Sec. Gynecological Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1534247
This article is part of the Research TopicPrognostic Biomarkers and Gene Signatures in Endometrial, Ovarian, and Cervical CancerView all 14 articles
The final, formatted version of the article will be published soon.
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Sialylation has been linked to cervical dysplasia, while its involvement in cervical cancer is uncertain. Hence, the aim of this study was to develop a prognostic model based on sialylation-related characteristics for cervical cancer patients and investigate how sialylation-related genes are altered in cervical cancer via analyses of transcriptome and single-cell RNA sequencing (scRNA-seq) data. The current work incorporated 4 transcriptome datasets relevant to cervical cancer (including scRNA-seq) and 110 sialylation-related genes (SRGs). Initially, differentially expressed SRGs (DE-SRGs) were discovered by differential expression analysis, among other methods. Subsequently, least absolute shrinkage and selection operator (LASSO) and Cox regression analysis was applied using DE-SRGs to detect prognostic genes and build prognostic models. Next, independent prognosis test was conducted, and a nomogram model was built using clinical characteristics and risk scores. Meanwhile, scRNA-seq was applied to examine the cellular composition and cell-to-cell regulation in cervical cancer vs normal group, and key cells were determined via prognostic genes and their differentiation process was investigated. Finally, the immunological microenvironment, mutant genes, and medication sensitivity were assessed. Clinical samples were taken to assess the expression of prognostic genes by quantitative reverse transcriptase PCR (qRT-PCR); First, we detected 19 DE-SRGs related with sialylation. Three prognostic genes, GALNT12, GCNT4, and NPL, were discovered by LASSO cox regression. A risk model constructed with prognostic genes revealed that patients in high-risk group had a much poorer survival rate than those in group with low risk. Meanwhile, low-risk cervical cancer patients were more likely to respond to immunotherapy and chemotherapy, depending on immunology, tumor microenvironment, and drug sensitivity. ScRNA- seq data suggests that the expression of prognostic genes was higher in key cells, macrophages and fibroblasts, and played a more critical role in cervical cancer. The findings from qRT-PCR demonstrated that GCNT4 and NPL were considerably overexpressed in the cervical cancer group. In this research, GALNT12, GCNT4 and NPL were discovered as sialylation-related prognostic genes in cervical cancer, providing novel pathways for detection and treatment.
Keywords: cervical cancer, sialylation, Prognostic features, Immunotherapy, mechanisms
Received: 25 Nov 2024; Accepted: 03 Apr 2025.
Copyright: © 2025 Muhetaer, He, Yang, Guo and An. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Ruifang An, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Supplementary Material
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.